ATE477795T1 - Magenretentionssystem mit kontrollierter arzneimittelfreisetzung - Google Patents

Magenretentionssystem mit kontrollierter arzneimittelfreisetzung

Info

Publication number
ATE477795T1
ATE477795T1 AT02751608T AT02751608T ATE477795T1 AT E477795 T1 ATE477795 T1 AT E477795T1 AT 02751608 T AT02751608 T AT 02751608T AT 02751608 T AT02751608 T AT 02751608T AT E477795 T1 ATE477795 T1 AT E477795T1
Authority
AT
Austria
Prior art keywords
core
drug
controlled drug
drug release
retention system
Prior art date
Application number
AT02751608T
Other languages
English (en)
Inventor
Kamlesh Dudhara
Nitin Dharmadhikari
Vaishali Dhavse
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Application granted granted Critical
Publication of ATE477795T1 publication Critical patent/ATE477795T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02751608T 2001-07-04 2002-07-04 Magenretentionssystem mit kontrollierter arzneimittelfreisetzung ATE477795T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN612MU2001 2001-07-04
PCT/IN2002/000144 WO2003011255A1 (en) 2001-07-04 2002-07-04 Gastric retention controlled drug delivery system

Publications (1)

Publication Number Publication Date
ATE477795T1 true ATE477795T1 (de) 2010-09-15

Family

ID=32051199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751608T ATE477795T1 (de) 2001-07-04 2002-07-04 Magenretentionssystem mit kontrollierter arzneimittelfreisetzung

Country Status (17)

Country Link
US (2) US7776345B2 (de)
EP (2) EP2238975B1 (de)
JP (2) JP4994570B2 (de)
KR (1) KR20040018394A (de)
CN (1) CN1520286B (de)
AT (1) ATE477795T1 (de)
AU (1) AU2002355686B2 (de)
BR (1) BR0211317A (de)
CA (1) CA2452738C (de)
DE (1) DE60237372D1 (de)
ES (1) ES2398348T3 (de)
HU (1) HUP0500795A3 (de)
MX (1) MXPA03012041A (de)
PL (1) PL370793A1 (de)
RU (1) RU2325152C2 (de)
WO (1) WO2003011255A1 (de)
ZA (1) ZA200400799B (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
MXPA03011566A (es) 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
RU2325152C2 (ru) * 2001-07-04 2008-05-27 Сан Фармасьютикл Индастриз Лимитид Удерживаемая в желудке система регулируемой доставки лекарственного средства
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CZ20041175A3 (cs) * 2002-06-04 2005-04-13 J.B. Chemicals & Pharmaceuticals Ltd. Farmaceutická kompozice pro systém pro řízené dávkování léčiva a způsob její výroby
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
KR20110097942A (ko) 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
EP2354120A1 (de) 2003-08-20 2011-08-10 XenoPort, Inc. Synthese von Acyloxyalkylcarbamat-Prodrugs und Zwischenprodukten davon
EP1658034A4 (de) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
EP1691790A1 (de) * 2003-12-12 2006-08-23 Penwest Pharmaceuticals Company Torsemid-dosierformen mit verzögerter freisetzung
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
EP1778196A4 (de) * 2004-07-26 2008-12-17 Teva Pharma Pharmazeutische dosierungsformen mit rasagilin
EA201001086A1 (ru) 2004-08-13 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
US20080020041A1 (en) * 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
US7494985B2 (en) 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US7566738B2 (en) 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
EP1811986B1 (de) 2004-11-04 2014-03-26 XenoPort, Inc. Orale darreichungsformen von gabapentin-prodrug mit verzögerter freisetzung
US20080153779A1 (en) 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
EP1690540A1 (de) * 2005-02-15 2006-08-16 Neuro3D Zusammensetzung enthaltend Ocaperidon
EP1909770B1 (de) * 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Kontrolliert freigesetzte, orale zusammensetzung mit levetiracetam
CA2901244A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
WO2007048223A2 (en) * 2005-10-25 2007-05-03 Pharmascience Inc. A gastric retention drug delivery system
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
AU2007201808B8 (en) 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
SG174026A1 (en) 2006-08-03 2011-09-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022171A1 (en) * 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
SI3103448T1 (sl) * 2006-09-26 2019-11-29 Novartis Ag Farmacevtski sestavek, ki vsebuje modulator S1P
WO2008074153A1 (en) 2006-12-18 2008-06-26 Electronic Dietary Foods Inc. Device for delivery of a substance
NZ598728A (en) * 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
DE102007026037A1 (de) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
HUP0700469A2 (en) * 2007-07-09 2009-04-28 Richter Gedeon Nyrt Floating pharmaceutical composition of sustained release containing metronidazol
EP2192892A2 (de) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsierende im magen gehaltene dosierformen
US20110287097A1 (en) * 2007-08-14 2011-11-24 Dr. Reddy's Laboratories, Inc. Pharmaceutical compositions comprising ropinirole
US20120003307A1 (en) * 2007-11-29 2012-01-05 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
EP2065038A1 (de) * 2007-11-30 2009-06-03 Pharnext Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
US9457048B2 (en) * 2008-02-05 2016-10-04 Wellosophy Corporation Absorbent ingestible agents and associated methods of manufacture and use
US8771730B2 (en) 2008-04-18 2014-07-08 Intec Pharma Ltd. Carbidopa/Levodopa gastroretentive drug delivery
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
WO2009158625A2 (en) * 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
CA2724533C (en) * 2008-07-24 2014-07-29 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
KR101687781B1 (ko) * 2008-08-15 2016-12-20 데포메드 인코퍼레이티드 Ｃｎｓ 장애의 치료 및 예방을 위한 위 체류성 약학적 조성물
PL2378883T3 (pl) * 2008-12-04 2016-06-30 Intec Pharma Ltd SYSTEM DOSTARCZANIA LEKU ZATRZYMYWANEGO W ŻOŁĄDKU dLA ZALEPLONU
CA3014688A1 (en) 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of aggression, irritability, or impulsivity
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
US20100297195A1 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
BRPI1009367A2 (pt) * 2009-05-27 2016-03-08 Dasan Medichem Co Ltd tablete de camada múltipla
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20110104273A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
CN102791258B (zh) * 2010-02-03 2018-05-08 图必制药公司 雷沙吉兰的延长释放制剂及其用途
CA2790164A1 (en) * 2010-02-17 2011-08-25 Sun Pharma Advanced Research Company Ltd. Method of treating a disease condition susceptible to baclofen therapy
US8748472B2 (en) * 2010-03-31 2014-06-10 Supernus Pharmaceuticals, Inc. Stabilized formulations of CNS compounds
KR101270751B1 (ko) * 2010-05-06 2013-06-07 (주)비씨월드제약 위 체류 및 방출 조절을 위한 조성물
US20130078290A1 (en) 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
HRP20151321T1 (hr) 2011-01-20 2016-01-29 Bionevia Pharmaceuticals Inc. Epalrestat ili njegov derivat u oblicima s prilagođenim otpuštanjem te postupci uporabe istih
AT511671A1 (de) * 2011-07-13 2013-01-15 Bischof Georg Dr Zusammensetzung zur erzeugung einer vorübergehenden okklusion des darms eines säugetiers
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
RU2489147C2 (ru) * 2011-08-31 2013-08-10 Людмила Петровна Лазурина Фармацевтическая антибактериальная композиция для местного применения на основе активных биометаллокомплексов
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN102440976A (zh) * 2011-12-21 2012-05-09 南京海陵中药制药工艺技术研究有限公司 依帕司他缓释片及其制备方法
PT2838517T (pt) * 2012-04-18 2018-01-04 Contera Pharma Aps Formulação farmacêutica disponível sob forma oral adequada para a melhoria da gestão dos distúrbios da mobilidade
US9918937B2 (en) * 2013-01-30 2018-03-20 Daewoong Co., Ltd. Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
WO2016132217A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of improving gaba-b receptor agonist therapy
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения
CA3030089C (en) 2016-07-11 2024-04-23 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
FR3054218B1 (fr) * 2016-07-22 2020-03-06 Universite De Rouen Procede de dedoublement de sels de baclofene
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
CA3036356A1 (en) 2016-09-09 2018-03-15 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
WO2018127594A1 (en) * 2017-01-06 2018-07-12 Oystershell Nv Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation
EP3345591A1 (de) * 2017-01-06 2018-07-11 Oystershell NV Orale dosierform für eine erhöhte löslichkeit eines schwerlöslichen wirkstoffs und verfahren zur herstellung
US11554114B2 (en) 2017-03-31 2023-01-17 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredients
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
DK3648747T3 (da) * 2017-06-16 2022-11-28 Amneal Complex Products Res Llc Gastroretentive doseringsformer til vedvarende frigivelse af lægemidler
US10987311B2 (en) * 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
DK3678648T3 (da) * 2017-09-08 2023-09-11 Insignis Therapeutics Inc Fremgangsmåder til anvendelse af dipivefrin
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CN113476421B (zh) * 2017-12-29 2023-04-07 江苏恒瑞医药股份有限公司 一种非布司他的控释组合物及其制备方法
WO2019246145A1 (en) * 2018-06-18 2019-12-26 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
EP3810111A4 (de) * 2018-06-19 2022-03-23 National University of Singapore Formulierungen von 5-hydroxytryptophan (5-htp) zur besseren bioverfügbarkeit für verschiedene indikationen
EP3970701B1 (de) 2018-06-27 2025-05-07 Amneal Complex Products Research LLC Selbstregulierende osmotische gastroretentive arzneimittelabgabesysteme
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
JP7535519B2 (ja) * 2018-12-18 2024-08-16 ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー メチルセルロースを含む徐放性組成物
CA3139217A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
RU2751163C9 (ru) * 2020-04-06 2021-10-20 Общество С Ограниченной Ответственностью "Ниармедик Плюс" Фармацевтическая композиция на основе макозинона для лечения туберкулеза, включая его формы с множественной и широкой лекарственной устойчивостью.
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
MX2024006405A (es) * 2021-11-25 2024-06-05 Orexa B V Unidad de dosificacion oral gastrorretentiva que contiene un anestesico local.
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法
CN115444831B (zh) * 2022-10-25 2023-08-22 南京康川济医药科技有限公司 一种依帕司他胃漂浮片及其制备方法
CN115721621A (zh) * 2022-12-16 2023-03-03 杭州剂泰医药科技有限责任公司 一种依帕司他缓释制剂
CN117137877A (zh) * 2023-10-09 2023-12-01 重庆士立德医药科技有限公司 一种巴氯芬缓释片及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101650A (en) 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
EP0205336B1 (de) * 1985-06-11 1991-09-11 Teijin Limited Oral-Arzneizubereitung mit Retardwirkung
JPS62195323A (ja) 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
JPH0798742B2 (ja) 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US4892739A (en) * 1988-04-25 1990-01-09 Ciba-Geigy Corporation Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
AU3990895A (en) * 1995-12-05 1997-06-27 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
US6271278B1 (en) 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
IN186245B (de) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
EP1063973B1 (de) * 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Zweiphasiges kontrolliertes verabreichungssystem für hochlösliche arzneimittel und verwandtes verfahren
CA2343760A1 (en) 1998-09-14 2000-03-23 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
AU765909C (en) * 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
AU2199500A (en) * 1998-12-23 2000-07-31 Alza Corporation Gastric retention dosage form having multiple layers
WO2001008670A2 (en) * 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
WO2001010405A1 (en) 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
EP1095650A1 (de) * 1999-10-29 2001-05-02 Universiteit Leiden Zweiphasensystem mit kontrollierter Freigabe
RU2325152C2 (ru) * 2001-07-04 2008-05-27 Сан Фармасьютикл Индастриз Лимитид Удерживаемая в желудке система регулируемой доставки лекарственного средства
KR20110097942A (ko) * 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
AU2007201808B8 (en) * 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity

Also Published As

Publication number Publication date
EP2238975B1 (de) 2012-12-05
HUP0500795A2 (en) 2007-02-28
RU2003138075A (ru) 2005-06-10
JP2010090161A (ja) 2010-04-22
ZA200400799B (en) 2005-07-27
CA2452738A1 (en) 2003-02-13
ES2398348T3 (es) 2013-03-15
AU2002355686B2 (en) 2007-11-29
MXPA03012041A (es) 2004-03-26
JP2004538301A (ja) 2004-12-24
DE60237372D1 (de) 2010-09-30
KR20040018394A (ko) 2004-03-03
HUP0500795A3 (en) 2008-04-28
US20100305208A1 (en) 2010-12-02
CN1520286A (zh) 2004-08-11
EP1411901A1 (de) 2004-04-28
US7776345B2 (en) 2010-08-17
JP4994570B2 (ja) 2012-08-08
US20040180088A1 (en) 2004-09-16
PL370793A1 (en) 2005-05-30
EP1411901B1 (de) 2010-08-18
US8012496B2 (en) 2011-09-06
EP2238975A1 (de) 2010-10-13
CA2452738C (en) 2011-06-14
CN1520286B (zh) 2010-12-01
BR0211317A (pt) 2004-12-14
WO2003011255A1 (en) 2003-02-13
RU2325152C2 (ru) 2008-05-27

Similar Documents

Publication Publication Date Title
DE60237372D1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
DE69917866D1 (de) Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
ATE251449T1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
DK1121099T3 (da) I maven hvilende farmaceutiske præparater til kontrolleret frigivelse
MY148867A (en) Gastric retention drug delivery system
NO995313L (no) Mikroartikler nyttige som ultrasoniske kontrastmidler og til levering av legemidler i blodbanen
ATE300286T1 (de) Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
DE69619668D1 (de) Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
WO2003028660A3 (en) Drug delivery devices and methods
DK0938316T3 (da) Opioidantagonistholdig galenisk formulering
IS5577A (is) Omeprazól örkorn vernduð gegn magasýrum, framleiðsluferli og lyfjasamsetningar
BG108516A (en) Pharmaceutical formulation
WO2007034503A3 (en) Controlled release dosage formulation of duloxetine
ATE361060T1 (de) Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
WO2005007074A3 (en) Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
DK0976395T3 (da) Tablet til langvarig afgivelse af et lægemiddel i maven
WO2007048223A3 (en) A gastric retention drug delivery system
WO2004062552A3 (en) Pharmaceutical composition containing a nsaid and a benzimidazole derivative
WO2003096968A3 (en) Oral osmotic controlled drug delivery system
MXPA06007511A (es) Revestimientos de granulos de farmaco que imparten resistencia a la embarradura durante la compresion mecanica.
CA2271569A1 (en) Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
WO2007057762A3 (en) Osmotic bi-layer tablet
EA200401145A1 (ru) Оральная фармацевтическая композиция с модифицированным высвобождением

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties